Additionally, we screened out four differential expression and prognosis-related m6A regulators (METTL14, YTHDC2, ZC3H13 and RBM15) through differential expression analysis and survival analysis, examined the therapeutic benefits of ICI therapy in AML patients with different METTL14, YTHDC2, ZC3H13 and RBM15 expression levels. The gene discussed is RBM15; the disease is acute myeloid leukemia.